📊 GALT Key Takeaways
Is GALT a Good Investment? Thesis Analysis
Galectin Therapeutics is a pre-revenue pharmaceutical company with severe financial distress, negative stockholders' equity of -$125.3M, and massive ongoing cash burn of -$17.8M annually. The company lacks meaningful revenue generation, has only 11.5M in cash reserves against 136.4M in liabilities, and faces imminent liquidity crisis with a current ratio of 0.09x.
Why Buy GALT? Key Strengths
- Maintains some cash reserves of $11.5M for near-term operations
- Relatively low capital expenditure requirements typical for biotech R&D stage
- Active insider trading activity (19 Form 4 filings in 90 days) suggests ongoing leadership engagement
GALT Investment Risks to Consider
- Negative stockholders' equity of -$125.3M indicates technical insolvency
- Severe liquidity crisis with current ratio of 0.09x and minimal cash relative to liabilities
- Continuous operating losses of -$17.8M annually with zero revenue generation creates unsustainable cash burn trajectory
- Liabilities of $136.4M vastly exceed total assets of $12.9M with no clear path to profitability
- Pre-revenue stage with no demonstrated commercial viability or product revenue
Key Metrics to Watch
- Cash balance depletion rate and runway months remaining
- Progress toward clinical trial endpoints and regulatory approvals
- Quarterly operating cash burn trends and cost reduction measures
- Debt restructuring negotiations or capital raise announcements
- Pipeline advancement and licensing/partnership deals to generate revenue
GALT Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
GALT Profitability Ratios
GALT vs Healthcare Sector
How GALECTIN THERAPEUTICS INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GALT Overvalued or Undervalued?
Based on fundamental analysis, GALECTIN THERAPEUTICS INC has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GALT Balance Sheet & Liquidity
GALT 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: GALECTIN THERAPEUTICS INC's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.74 indicates the company is currently unprofitable.
GALT Growth Metrics (YoY)
GALT Capital Allocation
GALT SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for GALECTIN THERAPEUTICS INC (CIK: 0001133416)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GALT
What is the AI rating for GALT?
GALECTIN THERAPEUTICS INC (GALT) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are GALT's key strengths?
Claude: Maintains some cash reserves of $11.5M for near-term operations. Relatively low capital expenditure requirements typical for biotech R&D stage.
What are the risks of investing in GALT?
Claude: Negative stockholders' equity of -$125.3M indicates technical insolvency. Severe liquidity crisis with current ratio of 0.09x and minimal cash relative to liabilities.
What is GALT's revenue and growth?
GALECTIN THERAPEUTICS INC reported revenue of N/A.
Does GALT pay dividends?
GALECTIN THERAPEUTICS INC does not currently pay dividends.
Where can I find GALT SEC filings?
Official SEC filings for GALECTIN THERAPEUTICS INC (CIK: 0001133416) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GALT's EPS?
GALECTIN THERAPEUTICS INC has a diluted EPS of $-0.40.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GALT a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, GALECTIN THERAPEUTICS INC has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GALT stock overvalued or undervalued?
Valuation metrics for GALT: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GALT stock in 2026?
Our dual AI analysis gives GALECTIN THERAPEUTICS INC a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GALT's free cash flow?
GALECTIN THERAPEUTICS INC's operating cash flow is $-17.8M, with capital expenditures of $0.0.
How does GALT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.09 (avg: 2).